Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that it has partnered with Glooko®, Inc. to connect Insulet’s Omnipod System user data with Glooko+diasend®, the most comprehensive diabetes data management system available, across Europe.
“Insulet and Glooko are dedicated to bringing innovation to diabetes management around the world. We are delighted to work together to provide Omnipod users across Europe the ability to remotely sync data from their Omnipod Systems using Glooko+diasend,” said DJ Cass, General Manager, Insulet Europe. “This combined platform makes their lives easier by allowing people with diabetes to review their blood glucose patterns on their smartphones and monitor the impact of their insulin regimen, diet and physical activity on their diabetes management.”
Insulet’s partnership with Glooko is further proof of its commitment to putting customers first, as it ensures Insulet can continue to be closer to the diabetes community and provide personalised support for Podders™ across Europe.
“Glooko has a long-standing relationship with Insulet and we are very excited to now expand our collaboration even further within the European markets,” said Anders Sonesson, General Manager Glooko Europe. “We are proud to support the Omnipod System with our universal data management solution and our seamless user experience will appeal to numerous health care providers and their patients throughout Europe, taking clinic workflow, remote patient monitoring and overall diabetes treatment plans to new heights.”
Glooko+diasend is currently used at approximately 7,000 provider sites by over 1.5 million users in 23 countries, and the system is offered in 15 languages.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.